Annual report pursuant to Section 13 and 15(d)

Revenue Recognition

v3.21.1
Revenue Recognition
12 Months Ended
Dec. 31, 2020
Revenue Recognition [Abstract]  
Revenue Recognition

 

3. Revenue Recognition

 

Revenue by Service Line

 

    Years Ended December 31,  
(in thousands)   2020     2019  
Functional neurosurgery navigation and therapy                
Disposable products   $ 6,271     $ 6,918  
Services     25       225  
Subtotal – Functional neurosurgery navigation and therapy     6,296       7,143  
Biologics and drug delivery                
Disposable products     1,468       1,522  
Services     3,575       890  
Subtotal – biologics and drug delivery revenue     5,043       2,412  
Capital equipment and software                
Systems and software products     1,050       1,356  
Services     440       306  
Subtotal – capital equipment and software revenue     1,490       1,662  
Total revenue   $ 12,829     $ 11,217  

 

Contract Balances

 

· Contract assets – Substantially all the Company’s contracts with customers are based on customer-issued purchase orders for distinct products or services. Customers are billed upon delivery of such products or services, and the related contract assets comprise the accounts receivable balances included in the accompanying consolidated balance sheets.

 

· Contract liabilities – The Company generally bills and collects capital equipment and software-related service fees at the inception of the service agreements, which have terms ranging from one to three years. The unearned portion of such service fees are classified as deferred revenue.

 

During the year ended December 31, 2020, the Company recognized capital equipment and software-related service revenue of approximately $0.5 million which was previously included in deferred revenue in the accompanying consolidated balance sheet at December 31, 2019.

 

In September 2019, the Company entered into a Development Services Agreement with a customer under which the Company was entitled to bill the customer for an upfront payment of $0.13 million, of which approximately $0.05 million and $0.10 million are included in deferred revenue in the accompanying December 31, 2020 and 2019 consolidated balance sheets, respectively.

 

Also, in September 2019, the Company entered into a Letter of Intent, followed by a related Statement of Work (together with the Letter of Intent, the “Project Documents”) in November 2019, with a customer which is a stockholder (and, commencing in 2020, a noteholder, as described in Note 6) and whose then Chief Operating Officer was a member of the Company’s Board of Directors (and was subsequently replaced with the customer’s Chief Development Officer), to commence a product development project. Under the terms of the Project Documents, the Company was entitled to bill the customer for: (a) an upfront, nonrefundable payment of $0.5 million; and (b) quarterly service fees of $0.5 million commencing in the fourth quarter of 2019. In February 2020, the Company entered into a Supply Agreement and a Statement of Work (the “European SOW”) with a European affiliate of the customer. Under the terms of the European SOW, the Company was entitled to bill the customer on a quarterly basis, commencing in the first quarter of 2020, for service fees of $0.25 million. During 2020, the clinical trials contemplated by the Project Documents and the European SOW were delayed as a result of the COVID-19 pandemic. As a result, the Company agreed to reduce such quarterly service fees by an aggregate of $0.25 million through September 30, 2020. In November 2020, the Company entered into an addendum to the Project Documents and the European SOW that, among other provisions, set the customer’s aggregate at $0.7 million per quarter, effective October 1, 2020. The Company recognizes as revenue each of the upfront payments described in this paragraph in proportional relationship to the transaction prices of the performance obligations contained in the related agreements and recognizes as revenue the quarterly service fees described in this paragraph as stand-by services beginning in the quarter such services commenced. Based on the foregoing: (a) the Company recognized revenue of approximately $3.5 million and $0.5 million for the years ended December 31, 2020 and 2019, respectively; (b) accounts receivable from the customer amounted to approximately $0.1 million at each of December 31, 2020 and 2019; and (c) approximately $0.1 million and $0.6 million of the aggregate amount of all the payments described in this paragraph were included in deferred revenue in the accompanying consolidated balance sheets as of December 31, 2020 and 2019, respectively.

 

The Company offers an upgraded version of its software at no additional charge to customers purchasing a three-year systems service agreement. The transaction prices of the software and the service agreement were determined through an allocation of the service agreement price based on the standalone prices of the software and the service agreements customarily charged by the Company. The transaction price of the software was recognized as revenue upon its installation and comprised approximately $0.1 million and $0.2 million of unbilled accounts receivable at December 31, 2020 and 2019, respectively.

 

Remaining Performance Obligations

 

The Company’s contracts with customers, other than capital equipment and software-related service agreements discussed below, are predominantly for terms of less than one year. Accordingly, the transaction price of remaining performance obligations related to such contracts at December 31, 2020 are not material.

 

Revenue with respect to remaining performance obligations related to capital equipment and software-related service agreements with original terms in excess of one year and the upfront payments discussed under the heading “Contract Balances” above amounted to approximately $0.5 million at December 31, 2020. The Company expects to recognize this revenue within the next three years.